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ABSTRACT 10 
Surface - modified nanostructured lipid carriers (NLC) is a promising formulation to prolong the 11 
retention time of the therapeutic agent at the site of absorption. Chitosan-coated AmpB-loaded NLC 12 
(ChiAmpB NLC) were developed showing particle size of 394.4 ± 6.4 nm, encapsulation efficiency of 13 
86.0 ± 0.3 % and a drug loading of 11.0 ± 0.1 %. ChiAmpB NLC showed biphasic release behaviour 14 
with no significant change in its physical properties upon exposure to conditions simulating the 15 
gastrointestinal tract. Compared to pure AmpB, ChiAmpB NLC observed not only a comparable 16 
antifungal behaviour but showed superior safety profiles, with two times lesser toxicity to the red 17 
blood cells and ten times safer to the HT-29 cell line.  It was also successfully observed a translation 18 
of the in vitro mucoadhesion result to the ex vivo animal study in which ChiAmpB NLC results in 19 
higher percentage of retention in the small intestine compared to uncoated formulation. Together, 20 
the data strongly offered the possibility of having a non-toxic yet effective oral treatment for 21 
systemic fungal infections.  22 
 23 
 24 
 25 
 26 
 27 
INTRODUCTION 28 
Disseminated fungal infections account for 30 % of death in patients with weakened immune 29 
system, especially in those with cancer, HIV / AIDS and organ transplant patients (1,2). Despite the 30 
recent discovery of new antifungal agents, amphotericin B (AmpB) remains the gold standard for the 31 
treatment of invasive fungal infections (3).  32 
AmpB is currently administered intravenously stabilised in micelles or liposomes (Fungizone ®, 33 
Ambisome ®, Abelcet ® and Amphocil ®) and although effective, patients have to contend with 34 
severe side effects such as haemolysis, anaemia, fever, headache and kidney toxicity attributable to 35 
the mechanism of action of AmpB and the excipients in the formulation (4,5). Furthermore, 36 
drawbacks in terms of safety and cost means that this mode of delivering AmpB is not sustainable.  37 
Oral administration of AmpB has been recognised as a potential strategy of minimizing the side 38 
effects experienced by patients with the above formulations (6–12). However, attempts to formulate 39 
oral delivery system for AmpB have yet to be translated to the clinic. This impasse is mainly due to 40 
the physicochemical properties of AmpB, such as high molecular weight (924 Da), zwitterionic and 41 
amphipathic characteristics in addition to the asymmetrical distribution of hydrophobic and 42 
hydrophilic groups (13,14). Thus, oral administration of AmpB results in low bioavailability (<0.3 %), 43 
precluding any therapeutic usefulness to patients (12,15).  44 
Nanostructured lipid carriers (NLC) is are the second generation solid lipid nanoparticles (SLN) 45 
derived from admixture of solid lipid and liquid oil. NLC presents a combination of controlled drug 46 
release, high drug loading, good biocompatibility and stability (16,17). Due to the advantages offered 47 
by the NLC, there are attempts by researchers to encapsulate AmpB within NLC (18–21). Orally 48 
administered dosage forms may present a short transit at the absorption window within the 49 
duodenum and in such cases, absorption is not maximised. Prolonged gastrointestinal retention at 50 
the site of absorption may improve the chances of uptake/absorption across the epithelium. 51 
Bioavailability is potentially improved so that the need for multiple administrations is negated 52 
(22,23). Surface modification of dosage forms using synthetic or natural polymers may be used to 53 
delay their transit within the gastrointestinal tract and possibly, maximise uptake as presented 54 
above (24). Chitosan is a natural cationic polymer with documented mucoadhesive properties (25). It 55 
has successfully been used to promote the in vivo absorption of insulin-loaded SLN via its 56 
mucoadhesive effect in the gastrointestinal tract (26). Besides, chitosan-coated NLC showed a delay 57 
in the ocular clearance and an improved bioavailability of flurbiprofen compared to the uncoated 58 
NLC (22).  59 
We previously reported on the design of both uncoated and chitosan-coated AmpB-loaded NLC 60 
(18). Although in general, NLC and chitosan meet the pre-requisites as safe nanocarriers, the clinical 61 
evidence for this safety, whilst crucial, is not always manifest in scientific reports (27–29). The 62 
present endeavour is aimed at deciphering the potential of the formulation as an oral delivery 63 
system of AmpB and subsequently, the effectiveness and toxicity of the formulation.  64 
MATERIALS AND METHODS 65 
Materials  66 
Amphotericin B was obtained from Fisher Scientific, India. The commercial formulation of 67 
amphotericin B deoxycholate (Amphotret®, Bharat Serums and Vaccines Limited, India) was a gift 68 
from Pahang Pharmacy, Malaysia. Beeswax and coconut oil were from Acros Organics, New Jersey, 69 
USA. Chitosan, (low molecular weight), phosphate buffered saline tablets (PBS), RPMI-1640 without 70 
L-glutamine and 3-(N-Morpholino) propanesulfonic acid (MOPS) were purchased from Sigma Aldrich 71 
Co. LLC., Missouri, USA. Soya lecithin was purchased from MP Biomedicals (Illkirch, France) and 72 
acetic acid was obtained from R&M Chemicals, India. Dulbecco’s Modified Eagle’s Medium (DMEM) 73 
was purchased from Nacalai Tesque Inc., Kyoto, Japan while Foetal Bovine Serum (FBS) was obtained 74 
from Tico Europe, Netherlands. All reagents and solvents used of analytical and HPLC grades 75 
respectively. Deionised water used was Milli-Q 18.2 MΩ.cm at 25 °C (Millipore Corp., Bedford, USA). 76 
Formulation of chitosan-coated AmpB-loaded NLC (ChiAmpB NLC) formulation 77 
AmpB-loaded NLC (AmpB NLC) was formulated by combination of homogenization and 78 
ultrasonication techniques as previously described (18). Briefly, 290 mg of beeswax and 10 mg of 79 
coconut oil were heated to 70 °C before the addition of AmpB. At the same time, 50 mg of Tween-80 80 
and 50 mg of lecithin were mixed with 10 mL of deionised water and stirred at 70 °C at 500 rpm for 81 
45 minutes.  The surfactant mixture was added into the melted lipids containing AmpB before being 82 
homogenized at 12 400 rpm for 8 minutes using high speed homogenizer (Ultra-Turrax T25, 83 
Germany). The coarse emulsion was further subjected to probe ultrasonication (Q500 QSonica, 84 
Newtown, CT, USA) for further 8 minutes at 20 % amplitude. The mixture was poured into 4 °C 85 
deionised water under 500 rpm of stirring, making up a total of 100 mL. Chitosan (dissolved in 1 % 86 
v/v acetic acid) was added in a dropwise manner into the formed AmpB NLC in 1: 40 v/v under 87 
stirring of 250 rpm or 15 minutes. Drug-free ChiNLC formulations were prepared as above but with 88 
the omission of AmpB. 89 
Characterisation of the formulations 90 
The particle size (z-average), polydispersity index (PDI) and zeta potential (ζ) were studied 91 
using the Zetasizer Nano ZS® (Malvern Instruments, UK) equipped with a 4-mV He-Ne laser at a 92 
wavelength of 633 nm. All samples were diluted in 1:20 v/v using deionised water and 93 
measurements were carried out in triplicate at 25 °C and the results were expressed as mean ± 94 
standard deviation.  Chemical transformations in chitosan, chitosan-coated NLC and NLC were 95 
assessed using Fourier transform infrared – attenuated total reflection (FTIR-ATR) equipped with 96 
ATR sampling accessory with a diamond crystal (Perkin Elmer, Waltham, USA). The freeze-dried 97 
formulations were placed directly to the ATR compartment and the spectra were recorded from 400 98 
- 4000 cm-1 at a resolution of 1 cm-1.  99 
Free AmpB was removed after precipitation of the formulation using acetonitrile, followed 100 
by centrifugation at 20 000 rpm for 10 minutes at 4 °C. The pellet containing the encapsulated AmpB 101 
was dissolved in DMSO:MeOH (1:1) and heated at 70 °C. The amount of AmpB entrapped within the 102 
particles was measured using an HPLC system (1260 Series, from Agilent technologies, Waldbronn, 103 
Germany, equipped with a 15 cm x 4.6 mm reversed-phase C-18 column, Hypersil Gold, 104 
ThermoFisher Scientific, Waltham, United States, 5 µm particle size stationary phase). Results are 105 
expressed as mean ± standard deviation. The linear regression of the calibration curve was obtained 106 
for AmpB at a concentration of 0.1-100.0 µg/mL in DMSO: MeOH (408 nm) with r2 of 0.9998. The 107 
encapsulation efficiency and drug loading were calculated as the following equations: 108 
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where, WT is the amount of AmpB in the system, WS is the amount of AmpB detected in the 111 
sediment and WN weight of nanoparticles obtained from freeze-dried sediments. 112 
Physical stability studies  113 
The formulations were stored at 4 °C and protected from light. After 15 months’ storage, 114 
aliquots were withdrawn and the particle size, PDI, ζ and encapsulation efficiency were evaluated. 115 
In vitro studies 116 
Amphotericin B release and stability studies 117 
The release of AmpB from ChiAmpB NLC was examined in relevant release medium (PBS, pH 118 
7.4 containing 1% Tween-80) where release of free AmpB in DMSO: MeOH was used as a control. 119 
Briefly, 50 µL of fresh ChiAmpB NLC formulation was mixed with 950 µL of release medium and 120 
gently shaken in rotary shaker (WiseCube®, Witeg Inc., Germany) at 37 °C. Tubes were removed at 121 
predetermined time intervals (15 min, 1, 2, 3, 4 and 5 hour), centrifuged at 20,000 rpm for 10 122 
minutes at 4 oC. and tThe amount of AmpB released was determined by analyzing the supernatants 123 
using the HPLC system described above. The experiment was carried out in triplicate and results 124 
were expressed as mean ± standard deviation. The amount of AmpB released was calculated as 125 
follows:  126 
Release of AmpB (%) = 100
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where, WS is the amount of AmpB detected in the sediment and WR is the amount of AmpB released 128 
in the supernatant.  129 
  The stability of the formulation in pH conditions simulating the relevant sections of the 130 
gastrointestinal tract was investigated by adding 50 µL of ChiAmpB NLC to 950 µL of acidic (pH 1.2, 131 
USP), near-acidic (pH 5.8, BP) or near-neutral (pH 6.8, BP) media representing the stomach, proximal 132 
and distal duodenum. The mixture was incubated at 37 °C and rotated at 120 rpm in rotary shaker 133 
(WiseCube®, Witeg Inc., Germany) for 2 hours. Aliquots were withdrawn from each medium and 134 
evaluated in terms of particle size and ζ as described above. 135 
Mucoadhesion studies 136 
A fall in ζ values was used as a measure of the extent of mucoadhesion between the 137 
formulations and mucin. This provided an insight of the mucoadhesive propensity of the formulation 138 
at relevant region within the gastrointestinal tract (30,31). The mucin used was type III porcine 139 
gastric mucin dispersed in pH 5.8 and 6.8 media (BP) under mild stirring at a concentration of 0.05, 140 
0.1, 0.25, 0.5, 0.75, 1.0 % w/v. Aliquots of formulations were mixed with each mucin concentration 141 
at 1:1 v/v ratio. The mixture was incubated at 37 °C for 2 hours in rotary shaker (WiseCube ®, Witeg 142 
Inc., Germany) operated at 120 rpm. The change in the ζ values was measured using the Zetasizer 143 
Nano ZS® (Malvern, UK) after appropriate dilution. Measurements were performed in triplicate and 144 
results were expressed as mean ± standard deviation. 145 
 146 
 147 
Antifungal studies 148 
The broth microdilution method was used to determine the minimum inhibitory 149 
concentration (MIC) of the formulation against Candida albicans (ATCC 90028) and based on the 150 
Clinical Laboratory Standards Institute (CLSI) guideline (M-27A). The broth medium was Roswell Park 151 
Memorial Institute (RPMI) 1640 with 0.165 M of MOPS [3-(N-morpholino) propanesulfonic acid]. The 152 
Candida albicans was grown aerobically in Sabouraud dextrose agar at 35 °C for 24 hours. The yeast 153 
inoculum was prepared by picking 5 colonies and suspended in 5 mL of sterile saline and the cell 154 
density was adjusted in accordance with 0.5 McFarland standard. The yeast suspension was diluted 155 
1:50 in sterile saline and further diluted 1:20 in broth medium, resulting in 0.5 x 103 to 2.5 x 103 156 
CFU/mL. 100 µL of the yeast suspension was loaded into the wells of the 96-well plates containing 157 
100 µL of AmpB resulting in final concentration of AmpB of 0.03125 – 16 µg/mL (Row 1-10). AmpB 158 
dissolved in DMSO was used as control. The stock solution of AmpB in DMSO was diluted using the 159 
broth medium, reducing the concentration of DMSO to 1%. Row 11 and 12 of the wells were used as 160 
controls; medium only and medium with yeast inoculum. The plates were incubated at 35 °C for 48 161 
hours. The MIC were determined at 24 and 48 hours by measuring the absorbance of the samples at 162 
530 nm using a UV-visible spectrophotometer (Epoch Microplate Spectrophotometer, Bio Tek 163 
Instruments, USA). Experiments were run in triplicate and results were expressed as mean ± 164 
standard deviation.  165 
Toxicity studies 166 
Haemolysis study 167 
Fresh blood samples were obtained from three healthy Sprague-Dawley male rats via cardiac 168 
puncture and erythrocytes (RBCs) were isolated by centrifugation at 3000 rpm for 10 minutes at 169 
4 °C. The supernatant along with buffy coat were pipetted and discarded. RBCs were washed thrice 170 
with phosphate buffered saline (PBS, pH 7.4) and dispersed in fresh PBS to obtain a 1 % haemotocrit. 171 
300 µL of the RBCs suspension was mixed with 300 µL of the formulations, giving final AmpB 172 
concentration in a range of 6.25 - 100 µg/mL. Pure AmpB dissolved in DMSO was used as control in 173 
which the final concentration of DMSO was reduced to < 0.01 % v/v using PBS. Deionised water with 174 
0.1 % v/v Triton-X was used as positive control (100 % haemolysis) while PBS solution was utilised as 175 
negative control (0 % haemolysis). The mixture of RBCs and formulations was incubated at 37 °C in a 176 
rotary shaker (WiseCube ®, Witeg Inc., Germany) at 100 rpm. The experiment was performed in 177 
triplicate. After predetermined time interval of incubation, any haemolysis was stopped by 178 
immersion of the sample tubes into ice water bath (0 °C) and unlysed RBCs were removed by 179 
centrifugation at 3000 rpm for 10 minutes. The haemoglobin released in the supernatant was 180 
collected and absorbance measured at 580 nm using a UV-visible spectrophotometer (Epoch 181 
Microplate Spectrophotometer, Bio Tek Instruments, USA) (32,33). The percentage of haemolysis 182 
was calculated according to the following equation.  183 
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where, Abss is the absorbance of the sample, Abs0 is the absorbance of 0 % lysed sample treated 185 
with PBS (pH 7.4) and Abs100 is the absorbance of 100 % lysed sample treated with deionised water 186 
with 0.1 % v/v Triton X-100.  187 
Cytotoxicity study 188 
The cytotoxicity effect of the formulations was evaluated against HT-29 cells using 3-(4,5-189 
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium bromide (MTT) assay. A 200 µL aliquot of cell 190 
suspension was seeded into 96-well plate at 5000 cells per well and incubated for 24 hours at 37 °C 191 
prior to drug treatment. The culture medium was replaced with 180 µL of fresh media before adding 192 
20 µL of formulations, achieving final concentration of AmpB in a range of 6.25 - 100 µg/mL. The 193 
mixture was incubated at 37 °C, 70 % humidity and 5 % carbon dioxide. Pure AmpB dissolved in 194 
DMSO were also studied with the final concentration of DMSO being reduced to 0.01 %v/v. Pure 195 
medium and medium containing cells were used as negative controls. At predetermined time 196 
interval of incubation, 20 µL of MTT solution (5 mg/mL) was added and the mixture was further 197 
incubated for 4 hours at 37 °C. The medium was removed and 100 µL of DMSO was added to 198 
dissolve the formazan crystals. The cell viability was assessed by measuring the absorbance of the 199 
solution at a wavelength of 570 nm (Epoch Microplate Spectrophotometer, Bio Tek Instruments, 200 
USA) with 630 nm used as reference wavelength. The cell viability was calculated based on the 201 
equation below.  202 
Cell viability (%) = 
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where, Abss is the absorbance obtained from the sample and Absc is the absorbance obtained from 204 
the control.  205 
Animal study 206 
Ex vivo intestinal adhesion studies 207 
An ex vivo mucoadhesion study was conducted on excised intestinal tissue of rats so as to 208 
further validate the in vitro studies above. Six Sprague-Dawley male rats weighing 250-300 g were 209 
sacrificed and intestinal tissue excised. The animals used for the study were obtained from the 210 
animal house facility of the University of Putra Malaysia with prior approval from Animal Welfare 211 
and Ethical Review Body of University of Nottingham, UK (UMNC 19). Six centimetres of the jejunum 212 
was flushed with 10 mL of ice-cold phosphate buffer and everted using stainless steel rod. Both ends 213 
of the jejunum segment was ligated and the sac was filled with 1.5 – 2 mL of Dulbecco’s Modified 214 
Eagle’s Medium (DMEM). The tissue was immersed in a 50 mL centrifuge tube containing 5 mL of 215 
DMEM and maintained at 4 °C. 10 mL of formulation was added into the tube and was incubated at 216 
37 °C for 30 minutes at 120 rpm in rotary shaker (WiseCube ®, Witeg Inc., Germany). The uncoated 217 
formulation was used as control. The sac was removed and the content in the tube was precipitated 218 
using acetonitrile, centrifuged at 10 000 rpm for 15 minutes and washed with deionized water. The 219 
precipitate was lyophilised and the unbound nanoparticles were weighed. The percentage of bound 220 
nanoparticles was calculated using the following equation:  221 
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where, WN is the initial weight of the nanoparticles and WU is the weight of the unbound 223 
nanoparticles. The animal used in this phase of the work were fresh cadavers used in a separate 224 
investigation so that no animals were sacrificed solely for this work. An Ethical Clearance was sought 225 
prior to commencement of the work, nonetheless. 226 
Statistical analyses 227 
Statistical evaluation was performed using one-way analysis of variance (ANOVA), Tukey’s post 228 
hoc test was conducted for multiple comparison between groups and differences were considered 229 
significant when p < 0.05. All calculations were conducted using IBM SPSS Statistics 24 (IBM 230 
cooperation, New York, NY).  231 
RESULTS AND DISCUSSION 232 
Figure 1 shows the FTIR-ATR spectra of pure chitosan, NLC and ChiNLC formulations. The 233 
characteristic bands for chitosan were observed at 3284, 1646 and 1557 cm-1 indicating a stretching 234 
of –OH groups, C=O from amide I, N-H bending and C-N stretching from amide II, respectively 235 
(23,31,34). In contrast to the NLC, we observed two distinctive peaks of amide I and II at 1635 and 236 
1539 cm-1 for ChiNLC. These two peaks are slightly shifted compared to those from pure chitosan. 237 
Hence, we inferred that the adsorption of chitosan was due to interactions between the amino 238 
group of the chitosan with the ester groups of the lipids. These findings are in accordance with 239 
results from other researchers (23,34).  240 
 241 
Figure 1:  FTIR-ATR spectra of (from top) drug-free NLC, drug-free ChiNLC and pure chitosan 242 
Both AmpB-loaded and drug free formulations of chitosan-coated NLC were evaluated based on 243 
particle size, polydispersity index (PDI), zeta potential (ζ), encapsulation efficiency and drug loading 244 
as shown in Table 1.  245 
Physical Properties ChiNLC ChiAmpB NLC 
Fresh Fresh 15 months 
Particle size (nm) 322.5 ± 4.5 394.4 ± 6.4* 231.0 ± 5.6* 
PDI 0.44 ± 0.03 0.44 ± 0.03 0.42 ± 0.03 
Zeta potential (mV) 26.5 ± 0.4 18.8 ± 0.3* 9.8 ± 0.3* 
Encapsulation efficiency (%) - 86.0 ± 0.3 79.8 ± 0.3* 
Drug loading (%) - 11.0 ± 0.1 10.2 ± 0.03 
*p<0.05: statistical significance between fresh ChiAmpB NLC and 15-month formulation (mean ± 246 
S.D., n=3) 247 
 248 
 249 
 250 
 251 
 252 
Upon incorporation of AmpB, there was an increase in size of the ChiNLC from 322.5 ± 4.5 to 253 
394.4 ± 6.4 nm in accordance with reports from other studies (28,35). In general, aggregation of 254 
particles is often observed upon storage of nanoformulations where the systems move to stabilised 255 
states by lowering their surface area to volume ratio (36). Interestingly, the ChiAmpB NLC presented 256 
a lower size range and PDI value after 15 months of storage. This change  could attributed to 257 
rearrangement of the chitosan layer, which resulted in the formation of a more condensed particle 258 
(8,37). However, we cannot eliminate the possibility of some dissociation of the chitosan layer as 259 
well since a decrease in ζ was observed. Notwithstanding, the ChiAmpB NLC remained positively 260 
charged during the 15-month storage, which points to the retention of sufficient chitosan coating, 261 
enough to retain electrostatic repulsion and size. Previous studies have reported that cationic 262 
nanoparticles were easily attracted to negatively charged endothelial cells which further ease the 263 
absorption of the particles (38,39). Both ChiNLC and ChiAmpB NLC presented a positive ζ, which 264 
indicate that chitosan was successfully adsorbed onto the surface of the NLC formulations (34). 265 
Although ChiAmpB NLC registered a significant reduction in the ζ values after 15-month of storage, 266 
we believe that adequate electrostatic repulsion was maintained since the size of the formulation 267 
remained in the nano-range. Thus, the formulation appears stable and therefore suitable to be 268 
developed into oral delivery system (Table 1). The encapsulation efficiency of the ChiAmpB NLC was 269 
86.0 ± 0.33 % whilst the drug loading was 11.0 ± 0.1 % (Table 1). The high encapsulation efficiency 270 
and drug loading can be attributed to the crystal disorder offered by the liquid oil within the solid 271 
lipid, providing enough space to accommodate the AmpB (40–42). The disordered structure also 272 
prevents crystal growth so that expulsion of AmpB was checked during storage, with only 6.2 % 273 
expulsion after 15 months.  274 
The in vitro AmpB release studies were conducted in phosphate buffer with 1% Tween-80 to 275 
maintain sink condition and the release profile of the formulations are depicted in Figure 2.  276 
 277 
Figure 2: In vitro AmpB release from ChiAmpB NLC formulation and free AmpB. [mean ± S.D. (n=3)] 278 
 279 
 280 
The release of pure AmpB was used as a control and exhibited a rapid release of up to 100 % 281 
within 15 minutes. On the other hand, the ChiAmpB NLC showed biphasic release profiles, with burst 282 
release (27 %) observed within the first 15 minutes followed by a more extended release over 5 283 
hours, which is in accordance with other studies (43–45). We hypothesized that the burst effect 284 
observed was due to degradation of the thin chitosan coating (46) while the second phase of release 285 
corresponds to the diffusion of the AmpB from the lipidic core (47). The sustained release pattern of 286 
the ChiAmpB NLC was best fitted into zero order release model (r2 = 0.904) as compared to other 287 
mathematical models (first order, Higuchi and Korsemeyer-Peppas) (43). This profile is in accordance 288 
with studies by other researchers (43–45). The effect of variation in pH simulating the 289 
gastrointestinal tract on the changes in the physical properties of ChiAmpB NLC in terms of particle 290 
size and ζ is presented in Figure 3. pH 1.2 comprised of 0.03 M NaCl and 0.1 M HCl, portraying the 291 
dominant electrolyte of the gastric.  292 
 293 
Figure 3: Particle size and ζ of ChiAmpB NLC before and after exposure to simulated GI fluids 294 
[mean ± S.D., n=3; *p < 0.05, significantly different with the fresh sample] 295 
 296 
 297 
 298 
 299 
No significant change in the particle size was observed after the exposure of ChiAmpB NLC to pH 300 
1.2 for 2 hours (p = 0.138). At pH 5.8 and 6.8, the particle size increased significantly to 594.5 ± 14.5 301 
and 544.9 ± 14.6 nm respectively. However, this should not be a concern as the sizes remain in 302 
nanometre range. The ChiAmpB NLC showed a slight drop in ζ upon exposure to pH 1.2 followed by 303 
a significant decrease, reversing from positive ζ to negative upon exposure to pH 5.8 and 6.8. This 304 
reversal in magnitude of ζ is likely to impede mucoadhesion with cells, however exposure to acidic 305 
pH can be controlled through enteric encapsulation of the ChiAmpB NLC. This indicates the 306 
neutralisation of the positive charge on the fresh ChiAmpB NLC by the anions present in the 307 
phosphate buffer which further led to the increase in particle size observed (48). 308 
Figure 4 shows the change in the ζ values of ChiAmpB NLC after incubation in mucin 309 
solutions maintained at various pH. Mucin is negatively charged due to the presence of sialic acid 310 
while the ChiAmpB NLC has a positive ζ prior incubation due to the amine groups in chitosan as 311 
described earlier.  312 
 313 
Figure 4: In vitro mucoadhesion in simulated intestinal pH [mean ± S.D., n=3; *p < 0.05, 314 
significantly different from fresh sample and 0.05 %w/v mucin in pH 5.8 and 6.8] 315 
 316 
 317 
Any decrease in ζ value of the formulation will indicate interaction between amine groups of 318 
chitosan with mucin and reflecting mucoadhesive properties of ChiAmpB NLC (30). The ChiAmpB 319 
NLC showed a significant drop in ζ values in both pH conditions; from +18.8 ± 0.3 mV to -22.1 ± 0.3 320 
(pH 5.8) and -26.5 ± 0.3 mV (pH 6.8) at 0.05 % w/v mucin concentration, thus confirming the 321 
mucoadhesive propensity of the ChiAmpB NLC formulation. Noteworthy, a higher drop in ζ values 322 
was observed at pH 6.8 (Figure 4), reflecting stronger mucoadhesive properties of the ChiAmpB NLC 323 
formulation at this pH. This can be explained based on the variation in pH and charge of the mucin. 324 
Mucin has a pKa of 2.6 which was highly negatively charged at pH 6.8. This allowed the ionised 325 
functional groups of -COOH- of mucin to repel each other, making them more accessible for 326 
interactions with cationic moieties such as -NH3+ groups of chitosan which thus, resulted in stronger 327 
mucoadhesive effects (31,49).  328 
An ex vivo mucoadhesion study was also conducted as it will provide a direct insight on the 329 
behaviour of the formulation with a biological substrate presented as freshly excised small intestine 330 
of the rats (30). The uncoated AmpB NLC formulation was used as a control and ChiAmpB NLC 331 
formulation showed an 84.2 ± 5.1 % adhesion to the intestinal lining of the rats (Figure 5).  332 
 333 
Figure 5: Ex vivo mucoadhesion assay using everted intestinal sac. [*p < 0.05: significant difference 334 
between chitosan-coated and uncoated AmpB NLC formulations (mean ± S.D., n = 6] 335 
 336 
In contrast, the uncoated AmpB NLC showed 55.8 ± 16.1 % binding of nanoparticles upon 337 
incubation with everted intestinal sac of rats. This affirms the mucoadhesive propensity of ChiAmpB 338 
NLC which is attributable to the chitosan coating so that prolonged contact time with the intestinal 339 
would assure prolonged transit and hence enhanced ChiAmpB NLC uptake (39).  340 
The antifungal efficacy of the formulations was studied against the Candida albicans which is 341 
one of the predominant causative agents in systemic fungal infections. The minimum inhibitory 342 
concentration (MIC) values of the standard (AmpB in DMSO) were 0.25 and 0.5 µg/mL after 24 and 343 
48 hours, respectively which is in accordance with the other studies (32,33). Thus, it can be 344 
reasonably inferred that AmpB with concentration of < 0.5 µg/mL exhibited fungistatic effect while > 345 
0.5 µg/mL portrayed fungicidal behaviour. The drug-free ChiNLC did not elicit any antifungal 346 
behaviour. On the other hand, the MIC values of the ChiAmpB NLC mirror those from the standard, 347 
exhibiting 0.25 and 0.5 µg/mL after 24 and 48 hours, respectively. We may conclude that the 348 
antifungal efficacy of the AmpB was retained and not altered by the formulation processes.   349 
Haemolysis is one of the major toxicities manifested by AmpB which hinders its clinical 350 
applications. In our previous reports (9,18), we have proposed the possibility of delivering the nano-351 
carrier via the lymphatic route. Therefore, the likelihood of emptying intact ChiAmpB NLC to the 352 
systemic circulation is plausible. This warrants investigation on how the blood might respond to the 353 
formulation via a haemolysis study. The haemolysis of the pure AmpB was significantly higher than 354 
all the formulations studied, showing a minimum of 80 % haemolysis at concentration as low as 6.25 355 
µg/mL upon 3-hour incubation (Figure 6).  356 
 357 
Figure 6: Percentage haemolysis of formulations after 3 and 24-hour of incubation [mean ± S.D., 358 
n=3. *p<0.05: significant difference between percentage haemolysis of 1) ChiAmpB NLC at 3 and 359 
24-hour incubation and 2) pure AmpB and ChiAmpB NLC at equivalent concentration of AmpB 360 
after 24-hour incubation] 361 
 362 
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 366 
In contrast, both ChiNLC and ChiAmpB NLC did not show any sign of haemolysis after 3-hour of 367 
incubation, showing that the carrier is biocompatible and AmpB is well-encapsulated within the 368 
nanoparticles. Upon 24-hour incubation, no haemolysis was observed for ChiNLC and ChiAmpB NLC 369 
at concentration below 25 and 12.5 µg/mL respectively. Noteworthy, the haemolytic behaviour of 370 
ChiAmpB NLC was time-dependent since the percentage haemolysis at 24-hour increased 371 
significantly as compared to the 3-hour incubation particularly at high concentration of ChiAmpB 372 
NLC (> 25 µg/mL). This phenomenon is consistent with the extended release of AmpB observed in 373 
Figure 2 which is likely to further mitigate the side effects due to AmpB. Besides, there was a linear 374 
correlation between the concentration of ChiAmpB NLC with the percentage of haemolysis in which 375 
the highest concentration of ChiAmpB NLC (100 µg/mL) marked the highest haemolysis (53.2 ± 376 
1.6 %), which is in accordance with other studies (13,33). Nevertheless, the percentage of 377 
haemolysis of both ChiNLC and ChiAmpB NLC were significantly lower than the pure AmpB, showing 378 
that the carrier system offered 2-7 times less toxic effects on the RBC than the pure AmpB.  379 
Figure 7 shows the cytotoxic effect of ChiAmpB NLC and drug-free ChiNLC formulations 380 
compared to Amphotret® and pure AmpB in HT-29 cell line via MTT assay.  381 
 382 
Figure 7: Cytotoxicity of formulations after 48-hour incubation [mean ± S.D., n=3] 383 
 384 
 385 
 386 
 387 
The percentage of cell viability between ChiAmpB NLC and drug-free ChiNLC formulations were 388 
almost superimposable, albeit lower cell viability was observed from ChiAmpB NLC formulation, 389 
showing that the AmpB is well-encapsulated within the nanoparticles (50). This mirrors the sustained 390 
release of AmpB observed in ChiAmpB NLC, where about 20% release of AmpB remained sustained 391 
after 50 minutes. This slow release of AmpB is thus non-toxic to cells. The decrease in percentage of 392 
cell viability was dose-dependent as 100 µg/mL of ChiAmpB NLC observed the lowest cell viability. 393 
Despite the reduction in cell viability, the IC50 (50 % of cell growth inhibition) of ChiAmpB NLC was 394 
not detected up to the highest concentration studied, 100 µg/mL (51). In contrast, the IC50 for pure 395 
AmpB and Amphotret® were 12.5 and 25 µg/mL, respectively. Thus, we inferred that the ChiAmpB 396 
NLC was at least 4-10 times less cytotoxic than the pure AmpB and Amphotret®. This outcome is 397 
consistent with those from other studies (15,52,53). Besides, Amphotret® showed higher toxicity 398 
than the pure AmpB at concentrations above 50 µg/mL in which we hypothesized that it was due to 399 
surfactant (sodium deoxycholate) present in the Amphotret® (54,55). Thus, the low cell viability 400 
observed from Amphotret® resulted from the synergistic toxicity due to AmpB and sodium 401 
deoxycholate. Hence, along with haemolysis (Figure 6) we ascertained that the ChiAmpB NLC is a 402 
well-tolerated formulation based on the biocompatibility of the excipients and polyaggregated state 403 
of AmpB reported in previous study (18,56). 404 
CONCLUSION 405 
The ChiAmpB NLC formulation showed the potential for further studies through its desired 406 
physical and chemical stability. The combination of chitosan and NLC exhibited good 407 
biocompatibility through its non-toxic behaviour in haemolysis and cytotoxicity assays. Besides, the 408 
intrinsic antifungal properties of AmpB remained unaffected by the formulation process or the 409 
incorporation of chitosan. The mucoadhesive behaviour of the ChiAmpB NLC shows that we have 410 
conclusively illustrates d the translation of the in vitro mucoadhesion data to ex vivo animal study.  411 
Crucially, the ChiAmpB NLC is mucoadhesive in the small intestinal region, which makes it ideal for a 412 
delayed transit and possible maximised uptake in that region. 413 
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